FUKAMI TomoyoDepartment of Medicine Assistant Professor A in Medical School | |||
Last Updated :2024/05/15
Published Papers
- 【肺がん,悪性胸膜中皮腫,胸腺腫瘍】免疫チェックポイント阻害薬による非小細胞肺がんの術前治療と術後治療の使い分け深見 朋世; 須田 健一; 濱田 顕; 津谷 康大腫瘍内科 (有)科学評論社 32 (6) 625 - 630 1881-6568 2023/12
- 宗 淳一; 下治 正樹; 武本 智樹; 深見 朋世; 老木 華; 福田 祥大; 小原 秀太; 濱田 顕; 千葉 眞人; 伊藤 正興; 須田 健一; 光冨 徹哉; 津谷 康大肺癌 (NPO)日本肺癌学会 63 (5) 407 - 407 0386-9628 2023/10
- 須田 健一; 老木 華; 福田 祥大; 深見 朋世; 小原 秀太; 濱田 顕; 伊藤 正興; 千葉 眞人; 下治 正樹; 武本 智樹; 宗 淳一; 光冨 徹哉; 津谷 康大肺癌 (NPO)日本肺癌学会 63 (5) 412 - 412 0386-9628 2023/10
- 老木 華; 千葉 眞人; 宗 淳一; 深見 朋世; 福田 祥大; 小原 秀太; 濱田 顕; 伊藤 正興; 下治 正樹; 武本 智樹; 須田 健一; 光冨 徹哉; 津谷 康大肺癌 (NPO)日本肺癌学会 63 (5) 530 - 530 0386-9628 2023/10
- Akira Hamada; Kenichi Suda; Masaya Nishino; Keiko Obata; Hana Oiki; Tomoyo Fukami; Shota Fukuda; Toshio Fujino; Shuta Ohara; Takamasa Koga; Masato Chiba; Masaki Shimoji; Masaoki Ito; Toshiki Takemoto; Junichi Soh; Yasuhiro Tsutani; Tetsuya MitsudomiJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023/09INTRODUCTION: Approximately 10% of mutations in the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) are in-frame insertions in exon 20 (X20ins). These tumors usually do not respond to conventional EGFR-tyrosine kinase inhibitors (TKIs). Several novel EGFR-TKIs active for X20ins are in clinical development, including mobocertinib, which was recently approved by the US FDA. However, acquired resistance during treatment with these TKIs still occurs as in the case of EGFR-TKIs of earlier generations. METHODS: We chronically exposed Ba/F3 cells transduced with five most common X20ins (A763_Y764insFQEA, V769_D770insASV, D770_N771insSVD, H773_V774insNPH and H773_V774insH) to mobocertinib in the presence of N-ethyl-N-nitrosourea and searched for secondary EGFR mutations. We evaluated the efficacies of several EGFR X20ins inhibitors, including zipalertinib and sunvozertinib, against cells with acquired resistant mutations. RESULTS: All secondary mutations resulting in acquired resistance to mobocertinib were exclusively C797S in insFQEA and insSVD. However, in the case of other X20ins (insASV, insNPH and insH), T790M or C797S secondary mutations contributed to acquired resistance to mobocertinib. The emergence of T790M was more frequent in cells treated with lower drug concentrations. Sunvozertinib showed good activity against resistant cells with T790M. Cells with C797S were refractory to all EGFR-TKIs, except for erlotinib, which was active for insFQEA with C797S. CONCLUSIONS: T790M or C797S, depending on the original X20ins mutations, conferred acquired resistance to mobocertinib. Sunvozertinib may be the treatment of choice for patients with tumors resistant to mobocertinib because of T790M.
- 深見 朋世; 小島 史嗣; 廣田 晋也; 矢田 圭吾; 板東 徹; 松藤 凡日本呼吸器外科学会雑誌 (一社)日本呼吸器外科学会 36 (6) 706 - 710 0919-0945 2022/09Intrapulmonary bronchogenic cyst is a type of congenital cystic lung disease, and thoracoscopic surgery in infancy is recommended, but rarely experienced in practice. In the present case, we performed a surgical intervention for a prenatally diagnosed posterior mediastinal cystic lesion at the age of 1 year and 5 months. The 8K thoracoscope was used to perform a joint pediatric and respiratory surgery, and a cystic lesion was found rising from the S8 of the right lower lobe, which was diagnosed as an endobronchogenic cyst of the intrapulmonary type. Although the patient required a right lower lobe resection instead of S8 sectional resection due to adhesion with the inferior pulmonary vein, the dissection of the pulmonary artery and bronchus could be safely performed at each regional branch level by sharing high-definition images on a 70-inch large screen, and the thoracoscopic-assisted surgery was successfully completed. The magnification effect and zoom-up function provided by the 8K thoracoscope were considered to be very useful in securing a working space in the narrow thoracic cavity of children and in performing a highly accurate minimally invasive surgery.